Avantor to Distribute Quantum-Si’s Next-Generation Protein Sequencing™ Technology
November 20 2024 - 7:30AM
Business Wire
Agreement Expands Access to Pioneering
Proteomics Technology Across the U.S. and Canadian Markets
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, has announced a
distribution agreement with Avantor® (NYSE: AVTR), a global leader
in mission-critical products and services for the life sciences and
advanced technology industries. Through this collaboration, Avantor
will distribute Quantum-Si's Next-Generation Protein Sequencing
(NGPS) portfolio, providing researchers across all market segments
in the U.S. and Canada streamlined access to these innovative
proteomics solutions.
The distribution agreement enables Avantor to offer Quantum-Si’s
protein sequencing technology to a broad range of laboratories
focused on proteomics. Quantum-Si’s platform leverages
single-molecule sequencing technology, with applications across
protein and biomarker identification, antibody characterization,
protein barcoding and post-translational modification analysis, to
deliver unprecedented insights into protein structure and function,
empowering scientists in fields like drug discovery, diagnostics,
and clinical research.
“By making our portfolio available through Avantor, we are
expanding the reach of our Next-Generation Protein Sequencing
technology to a wider audience,” said Jeff Hawkins, President and
Chief Executive Officer of Quantum-Si. “We believe this agreement
will allow us to rapidly scale delivery of our innovative solutions
to more researchers, accelerating scientific discoveries and
advancements in critical research areas.”
“Avantor’s strong presence in the U.S. and Canada, combined with
its digital platforms and the expertise of their life sciences
team, will offer Quantum-Si customers direct access to a
comprehensive support system for implementing NGPS across diverse
research settings,” said Todd Bennett, Chief Commercial Officer of
Quantum-Si. “This agreement is a significant step forward in
scaling our business and expanding our reach, ensuring that our
cutting-edge technology is accessible to a wider range of
researchers and laboratories.”
For more information on Quantum-Si’s technology and research
applications, please visit The Protein Sequencing Company™ |
Quantum-Si
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company’s
Platinum® instrument enables Next-Generation Protein Sequencing™
that advances proteomic research, drug discovery, and diagnostics
beyond what has been possible with existing proteomic tools. Learn
more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company’s expectations with respect to future performance and
development and commercialization of products and services, its
anticipated cash runway and its financial guidance for the full
year 2024. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from those discussed in the forward-looking
statements. Most of these factors are outside the Company’s control
and are difficult to predict. Factors that may cause such
differences include, but are not limited to: the inability to
maintain the listing of the Company’s Class A common stock on The
Nasdaq Stock Market; the ability of the Company to grow and manage
growth profitably and retain its key employees; the Company’s
ongoing leadership transitions; changes in applicable laws or
regulations; the ability of the Company to raise financing in the
future; the success, cost and timing of the Company’s product
development and commercialization activities; the commercialization
and adoption of the Company’s existing products and the success of
any product the Company may offer in the future; the potential
attributes and benefits of the Company’s commercialized Platinum®
protein sequencing instrument and kits and the Company’s other
products once commercialized; the Company’s ability to obtain and
maintain regulatory approval for its products, and any related
restrictions and limitations of any approved product; the Company’s
ability to identify, in-license or acquire additional technology;
the Company’s ability to maintain its existing lease, license,
manufacture and supply agreements; the Company’s ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company’s products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others; the
Company’s estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company’s financial performance; and other risks and uncertainties
described under “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q and in the
Company’s other filings with the SEC. The Company cautions that the
foregoing list of factors is not exclusive. The Company cautions
readers not to place undue reliance upon any forward-looking
statements, which speak only as of the date made. The Company does
not undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
About Avantor®
Avantor®, a Fortune 500 company, is a leading global provider of
mission-critical products and services to customers in the
biopharma, healthcare, education & government, and advanced
technologies & applied materials industries. Our portfolio is
used in virtually every stage of the most important research,
development and production activities in the industries we serve.
Our global footprint enables us to serve more than 225,000 customer
locations and gives us extensive access to research laboratories
and scientists in more than 180 countries. We set science in motion
to create a better world. For more information, please visit
www.avantorsciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241120216613/en/
Investor Contact Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media Contact Katherine Atkinson, SVP, Commercial
Marketing media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Nov 2023 to Nov 2024